12:00 AM
Aug 05, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Adempas riociguat: Additional Phase III data

Additional data from the double-blind, international Phase III PATENT-1 trial in 443 patients with symptomatic PAH showed that thrice-daily oral riociguat with or without endothelin receptor antagonists/non-IV prostanoids significantly reduced PVR by 223 dyne*sec/cm5 vs. 9 dyne*sec/cm5 for placebo (p<0.001). Riociguat also significantly reduced NT-proBNP levels by 198 pg/mL vs. a 232 pg/mL increase for placebo (p<0.001) and significantly reduced Borg Dyspnea Score by 0.4 points...

Read the full 308 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >